Avoiding obsolescence in advanced prostate cancer management: A guide for urologists

BJU International

Volumn 115, Issue 2, 2015, Pages 188-197

  Shore, Neal D ^a   Karsh, Lawrence ^b   Gomella, Leonard G ^c   Keane, Thomas E ^d   Concepcion, Raoul S ^e   Crawford, E David ^f  

^a Carolina Urologic Research Center   (United States)

^b Urology Center of Colorado   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Urology Associates   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

abiraterone acetate; castration resistant prostate cancer; denosumab; enzalutamide; metastasis; sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; BICALUTAMIDE; CABAZITAXEL; DEGARELIX; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; MITOXANTRONE; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; SIPULEUCEL T; ZOLEDRONIC ACID; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ADVANCED PROSTATE CANCER; ALLERGIC REACTION; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BACKACHE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; BRONCHOSPASM; CANCER PALLIATIVE THERAPY; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL DECISION MAKING; CONSTIPATION; DEPRESSION; DESQUAMATION; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSESTHESIA; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; INFUSION RELATED REACTION; INJECTION SITE PAIN; INTERDISCIPLINARY COMMUNICATION; JAUNDICE; JAW OSTEONECROSIS; JOINT SWELLING; KIDNEY FAILURE; LEADERSHIP; LEUKOPENIA; LIVER TOXICITY; MEDICAL ONCOLOGIST; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PATIENT CARE; PATIENT MONITORING; PATIENT REFERRAL; PELVIC PAIN; PERIPHERAL EDEMA; PROSTATE CANCER; QT PROLONGATION; RASH; REVIEW; SEIZURE; SHOCK; STAFF TRAINING; SUDDEN CARDIAC DEATH; TACHYCARDIA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UROLOGIST; VOMITING; ADVERSE EFFECTS; BLOOD; BRACHYTHERAPY; CLINICAL PRACTICE; DISEASE MANAGEMENT; EARLY DIAGNOSIS; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PROSTATECTOMY; PROSTATIC NEOPLASMS; STANDARDS; TRENDS; UROLOGY; WATCHFUL WAITING;

BRACHYTHERAPY; DISEASE MANAGEMENT; EARLY DETECTION OF CANCER; GUIDELINE ADHERENCE; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; UROLOGY; WATCHFUL WAITING;

EID: 84921599451     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12665     Document Type: Review

References (31)

1. American Cancer Society. Cancer Facts & Figures 2013. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed 17 March 2014
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
3. Solo K, Mehra R, Dhawan J, Valant J, Scher HI,. Prevalence of prostate cancer (PC) clinical states (CS) in the United States: estimates using a dynamic progression model [Abstract]. J Clin Oncol 2011; 29 (Suppl.): Abstract 4637
4. TAXOTERE® (Docetaxel) Injection Concentrate [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC, 2012. Available at: http://products.sanofi.us/Taxotere/taxotere.html. Accessed 17 March 2014
5. Fitzpatrick JM,. Management of castration-resistant prostate cancer: a call to urologists. BJU Int 2012; 110: 772-774
6. ZYTIGA® (Abiraterone Acetate) Tablets [prescribing information]. Horsham, PA: Janssen Biotech Inc., 2013. Avialbale at: http://www.zytiga.com/sites/default/files/pdf/full-product-information.pdf. Accessed 17 March 2014
7. XTANDI® (Enzalutamide) Capsules [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc., 2012. Available at: http://www.astellas.us/docs/12A005-ENZ-WPI.PDF. Accessed 17 March 2014
8. PROVENGE® (Sipuleucel-T) Suspension [prescribing information]. Seattle, WA: Dendreon Corporation, 2011. Available at: http://www.dendreon.com/prescribing-information.pdf. Accessed 17 March 2014
9. JEVTANA® (Cabazitaxel) Injection [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC, 2013. Available at: http://products.sanofi.us/jevtana/jevtana.html. Accessed 17 March 2014
10. XGEVA® (Denosumab) Injection [prescribing information]. Thousand Oaks, CA: Amgen Inc., 2013. Available at: http://pi.amgen.com/united-states/xgeva/xgeva-pi.pdf. Accessed February 2014
11. Xofigo® (Radium Ra 223 Dichloride) Injection [prescribing information]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc., 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Xofigo-PI.pdf. Accessed 17 March 2014
12. Sartor AO, Fitzpatrick JM,. Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int 2012; 110: 328-335
13. CASODEX® (Bicalutamide) Tablet [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2009. Available at: http://www1.astrazeneca-us.com/pi/casodex.pdf. Accessed 17 March 2014
14. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822
15. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468
16. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512
17. Harrison MR, Wong TZ, Armstrong AJ, George DJ,. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013; 5: 1-14
18. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol 2013; 190: 429-438
19. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012; 48: 678-686
20. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210-1217
21. ZOMETA® (Zoledronic Acid) Injection [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf. Accessed 17 March 2014
22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Prostate Cancer, 2014 version 1. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed March 2014
23. LUPRON DEPOT® (Leuprolide Acetate) [prescribing information]. North Chicago, IL: Abbott Laboratories, 2013. Available at: http://www.lupron.com/prescribing-information.cfm. Accessed 17 March 2014
24. FIRMAGON® (Degarelix for Injection) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc., 2013. Available at: http://www.firmagon.us/assets/full-pi-0b53f4d2a48c52b3e4f87f5e3f340863.pdf. Accessed 17 March 2014
25. Eastham JA,. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177: 17-24
26. Srinivas S, Colocci N,. Bone related events in high risk prostate cancer. J Urol 2006; 176: S50-54
27. Body JJ,. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol 2010; 21 (Suppl. 7): vii180-185
28. Bagrodia A, Diblasio CJ, Wake RW, Derweesh IH,. Adverse effects of androgen deprivation therapy in prostate cancer: current management issues. Indian J Urol 2009; 25: 169-176
29. Woo HH,. Prostate cancer: are urologists ready to manage castration-resistant disease? Nat Rev Urol 2013; 10: 133-134
30. Taplin SH, Rodgers AB,. Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care. J Natl Cancer Inst Monogr 2010; 40: 3-10
31. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882